|
AMECRYS is a research project funded by the European Commissionunder the Horizon 2020 programme, in the framework of Future and Emerging Technologies actions (FET-OPEN), supporting early-stages of the science and technologyresearch and innovation around new ideas toward radically new future technologies.
|
|
|
The primary goal of the AMECRYS’ consortium is to contribute in revolutionizing currently used downstream practices in biopharmaceutical productions - mainly based on expensive and cumbersome multi-step batch chromatography platforms - by developing an innovative Continuous Template-Assisted Membrane Crystallization process as key-unit |
As ultimate scientific and technological results of the research strategy, AMECRYS’ network aims to boost medical advancement and to increase efficiency in biopharmaceutical productions by matching a twofold outcome:
- expanding fundamental knowledges in the crystallization mechanisms of large and structurally complex therapeutic bio-macromolecules, allowing an easier structural determination to get their biological function;
- giving a significant contribution to the assessment of crystallization as main purification step in the downstream processing of therapeutic proteins, with benefits in terms of production efficiency, product quality and reduction of production costs.
The research activity will be focused on the downstream processing of monoclonal antibodies (mAbs), one of the most important class of therapeutic proteins in modern medicine, which are used in a wide range of diseases including cancer, cardiovascular, autoimmune, and inflammation.
The AMECRYS network involves two public research organizations, four academic institutions, and three industrial from four European Countries.
The project runs for four years - from 1 October 2016 through 30 September 2020.
It is our great pleasure to share with you AMECRYS's scientific achievements.
Stay in touch!
On behalf of the Consortium,
Gianluca Di Profio (CNR-ITM, Italy)
AMECRYS' Coordinator
